Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 7/20 | 0.88 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.95 |
| ▸ | IDO1 | P14902 | 4/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625402 | 0.98 | TAAR1 (1.00) | TAAR1MAOBIDO1 | |
| Bromide SCHEMBL28801000 | 0.95 | TAAR1 (0.95) | TAAR1MAOBIDO1MIF | |
| Iodide SCHEMBL28689118 | 0.95 | TAAR1 (0.95) | TAAR1MAOBIDO1MIF | |
| Hydrochloric Acid SCHEMBL30558891 | 0.94 | MAOB (1.00) | TAAR1MAOBIDO1 | |
| Hydrochloric Acid SCHEMBL17042516 | 0.89 | TAAR1 (0.75) | TAAR1MAOBIDO1 | |
| Hydrochloric Acid SCHEMBL5154716 | 0.87 | TAAR1 (0.73) | TAAR1MAOBIDO1MIF | |
| SCHEMBL2872345 | 0.86 | TAAR1 (0.78) | TAAR1MAOBIDO1 | |
| SCHEMBL31377022 | 0.86 | TAAR1 (0.78) | TAAR1MAOBIDO1BLMKMT2A | |
| Acetic Acid SCHEMBL29202185 | 0.85 | TAAR1 (0.75) | TAAR1MAOBIDO1 | |
| SCHEMBL2025850 | 0.84 | TAAR1 (0.76) | TAAR1MAOBIDO1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122054880-A | Perovskite laminated solar cell, preparation method thereof and photovoltaic module | 通威太阳能（成都）有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-120018742-A | Perovskite surface sequential post-treatment method based on two-dimensional ligand modification materials with different polarities | 武汉理工大学 | 2025-05-16 | — | — | CN | claimed |
| CN-119546037-A | Perovskite passivation layer and preparation method thereof | 天合光能股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-117693271-A | Perovskite film and preparation method and application thereof | 极电光能有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-122054880-A | Perovskite laminated solar cell, preparation method thereof and photovoltaic module | 通威太阳能（成都）有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-120018742-A | Perovskite surface sequential post-treatment method based on two-dimensional ligand modification materials with different polarities | 武汉理工大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-119546037-A | Perovskite passivation layer and preparation method thereof | 天合光能股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119546037-A | Perovskite passivation layer and preparation method thereof | 天合光能股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-118829253-A | Perovskite solar cell, preparation method thereof and solar cell module | 比亚迪股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
| EP-0917530-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-19 | — | — | EP | disclosed |
| US-6046210-A | ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-04 | — | — | US | disclosed |
| EP-0917530-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-26 | — | — | EP | disclosed |
| WO-1997043262-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-11-20 | — | — | WO | disclosed |
| EP-0584066-A4 | ANTI-THROMBOTIC PEPTIDE AND PSEUDOPEPTIDE DERIVATIVES. | RHONE POULENC RORER INT (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0584066-A1 | ANTI-THROMBOTIC PEPTIDE AND PSEUDOPEPTIDE DERIVATIVES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992018117-A1 | ANTI-THROMBOTIC PEPTIDE AND PSEUDOPEPTIDE DERIVATIVES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| US-5086069-A | Platelet anticoagulants for blood and cardiovascular disorder | RORER PHARMACEUTICAL CORPORATION (US) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | MAOB 2836/4885TAAR1 241/4885IDO1 1362/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | MAOB 2778/4885TAAR1 238/4885IDO1 1352/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | MAOB 2778/4885TAAR1 238/4885IDO1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.